Phospholipase A2 group V · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-15Phospholipase A2 group V shows late clinical disease relevance led by acute coronary syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P39877. Start with acute coronary syndrome, then reuse UniProt P39877 as the stable protein anchor across project notes and exports.
Start with acute coronary syndrome, then reuse UniProt P39877 as the stable protein anchor across project notes and exports.
Phospholipase A2 group V shows late clinical disease relevance led by acute coronary syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with acute coronary syndrome because it currently carries late clinical support. Linked drugs include VARESPLADIB METHYL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPhospholipase A2 group V
Review this target as Phospholipase A2 group V, mapped to UniProt P39877. Sequence length is 138 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phospholipase A2 group V as ChEMBL target CHEMBL4323, mapped to UniProt P39877. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Phospholipase A2 group V is the right protein anchor across sources, using UniProt P39877 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute coronary syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Phospholipase A2 group V |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P39877 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Phospholipase A2 group V |
| UniProt Accession | P39877 |
| Component Type | Protein |
| Sequence Length | 138 aa |
Phospholipase A2 group V
Review this target as Phospholipase A2 group V, mapped to UniProt P39877. Sequence length is 138 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Phospholipase A2 group V shows late clinical disease relevance led by acute coronary syndrome. 2 more disease programs remain visible in the same review block.
Start review with acute coronary syndrome because it currently carries late clinical support. Linked drugs include VARESPLADIB METHYL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5172164 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL515637 | 7.46 | IC50 | 35.0 | Preclinical |
| CHEMBL148649 | 7.36 | IC50 | 44.0 | Preclinical |
| CHEMBL332993 | 7.0 | IC50 | 100.0 | Preclinical |
| CHEMBL514692 | 7.0 | IC50 | 100.0 | Preclinical |
| CHEMBL444450 | 6.96 | IC50 | 110.0 | Preclinical |
| CHEMBL148674 | 6.91 | IC50 | 124.0 | Clinical |
| CHEMBL446349 | 6.85 | IC50 | 140.0 | Preclinical |
| CHEMBL4205008 | 6.75 | IC50 | 180.0 | Preclinical |
| CHEMBL357979 | 6.57 | IC50 | 270.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 21 | 38 | 6.0 |
| assay format | 3 | 10 | 5.9 |
| cell-based format | 1 | 1 | 8.0 |